Quick summary
MOTS-c is a mitochondrial-derived peptide encoded within the 12S rRNA gene that activates AMPK to improve glucose uptake, insulin sensitivity, and fatty acid oxidation. It is not FDA-approved, is sold as a research peptide, and is often described as an 'exercise mimetic'.
Overview
MOTS-c is a mitochondrial-derived peptide (MDP) encoded within the 12S rRNA gene of mitochondrial DNA. Discovered in 2015 by Changhan David Lee at USC, it is one of the first identified peptides encoded by the mitochondrial genome rather than nuclear DNA. MOTS-c acts as a metabolic regulator, improving glucose metabolism, insulin sensitivity, and exercise capacity. It has been called an 'exercise mimetic' peptide.
Mechanism of action
MOTS-c activates AMPK (AMP-activated protein kinase), the master metabolic sensor that coordinates cellular energy metabolism. It enhances glucose uptake in skeletal muscle, improves insulin sensitivity, promotes fatty acid oxidation, and regulates the folate-methionine cycle affecting cellular methylation. Under metabolic stress, MOTS-c translocates to the nucleus where it regulates adaptive gene expression through interaction with ARE-containing promoters.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| metabolic optimization / exercise mimetic | subcutaneous | 5–10 mg | 3-5x weekly | Inject in the morning or pre-workout. Often combined with exercise protocol. 4-8 week cycles. Limited dosing data — extrapolated from animal studies. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Lee et al. (2015, Cell Metabolism) demonstrated MOTS-c prevents age-dependent and high-fat-diet-induced insulin resistance in mice. Subsequent studies showed improved exercise performance, skeletal muscle metabolism, and weight management. A 2020 study found higher circulating MOTS-c levels in long-lived populations. Human studies show MOTS-c increases during exercise, suggesting it mediates some exercise benefits. Animal lifespan studies show positive trends. Clinical trials are in early stages.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with MOTS-c for synergistic effects.
Legal status
Not FDA-approved. Available as a research peptide. Relatively new (discovered 2015) with limited regulatory attention.
Sourcing & access
Research compound
MOTS-c is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
MOTS-c is a mitochondrial-derived peptide (MDP) encoded within the 12S rRNA gene of mitochondrial DNA. Discovered in 2015 by Changhan David Lee at USC, it was one of the first identified peptides encoded by the mitochondrial genome rather than nuclear DNA.
MOTS-c activates AMPK, the master cellular energy sensor. It enhances glucose uptake in skeletal muscle, improves insulin sensitivity, promotes fatty acid oxidation, and under metabolic stress translocates to the nucleus to regulate adaptive gene expression through ARE-containing promoters.
MOTS-c is not FDA-approved for any indication. It is sold as a research peptide and is relatively new to the regulatory landscape, having only been discovered in 2015 by Changhan David Lee at USC. Clinical trials remain in early stages and no country has yet approved MOTS-c as a pharmaceutical or supplement ingredient.
Research protocols commonly use 5 to 10 mg subcutaneously 3 to 5 times weekly, often injected in the morning or pre-workout in 4 to 8 week cycles. Dosing data is limited and largely extrapolated from animal studies.
Reported side effects are generally mild and include injection site reactions, mild GI discomfort, and transient fatigue. Controlled human safety data is limited because clinical trials are still in early stages.
Research has shown that circulating MOTS-c levels rise during exercise and that the peptide mediates some of the metabolic benefits of exercise in animal studies. It is sometimes described as an 'exercise mimetic' for this reason, though human clinical data remains limited.
MOTS-c has an estimated half-life of approximately 4 hours based on animal pharmacokinetic studies. Formal human half-life data has not been published because clinical trials remain in early stages. This half-life supports the typical research protocol of dosing 3 to 5 times weekly rather than daily for metabolic and exercise-mimetic applications.
Research references
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistancePubMed
- MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolismReview
- The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic StressPubMed
- Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and agingReview
- MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasisPubMed